Becton, Dickinson and Company Launches Innovative Diabetes Pen Needle With Pentapoint 5-Bevel Technology
Oxford, UK (26 March 2014) – BD (Becton, Dickinson and Company), a leading global medical technology company, announced today the launch in the UK and Ireland of BD Micro-Fine Ultra™ with 5-bevel needle technology, clinically demonstrated to improve injection comfort for diabetes patients, and enhancing the injection advantages of the current BD Micro-Fine™+ Pen Needle .
A patient study found the five-bevel pen needles to be less painful, easier to insert and more comfortable, when compared with current three-bevel pen needles. This new Pentapoint™ 5-bevel technology is the next in a series of innovations to come from BD Medical – Diabetes Care, resulting in a BD Premium Pen Needle product line which will be called BD Micro-Fine Ultra™.
Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety . Also, patients who reported injection-related pain or embarrassment intentionally skipped insulin injections more often . The BD Micro-Fine Ultra™ Pen Needle with Pentapoint™ technology reduces skin penetration force by 23% on average, and is clinically demonstrated to reduce the pain of injection . This may help people with diabetes adhere to an insulin injection regimen and improve outcomes with greater comfort and ease of use.
The BD Micro-Fine Ultra™ with Pentapoint™ needle tip is specially designed with five-beveled edges to create a flatter, thinner surface to penetrate the skin with significantly greater ease, for a smoother and more comfortable injection experience, compared to previous generation three bevel needles. Pentapoint™ technology is available in 4mm pen needles.
Matthias Borst, VP / GM Europe, BD Medical - Diabetes Care, comments: “BD Diabetes Care has been a leader in diabetes injection devices for almost 90 years, and is committed to helping improve the injection experience for the millions of people living with diabetes, through ongoing patient education, the constant pursuit of innovation and improvement, and the development of high-quality products that make a difference. Building on the introduction of the BD Micro-Fine™+ 4mm Pen Needle in 2010, we are confident that our new Pentapoint™ technology will provide an even more comfortable injection experience, helping to minimise injection resistance, fear and anxiety in people with diabetes, enabling them more easily to adopt and adhere to the therapy regimens recommended to improve their diabetes care.”
The BD Micro-Fine Ultra™ 4mm Pen Needle is proven to be as effective as longer needles for patients of all body types , and provides equivalent glucose control by more effectively delivering the insulin dose to subcutaneous tissue (the layer of fat below the skin), the recommended site for insulin injections , and reducing the risk of injecting into muscle . Intramuscular injection can accelerate insulin absorption and increase the risk of hypoglycemia (abnormally low blood sugar) . Subcutaneous injection allows the insulin to be absorbed at an appropriate rate, resulting in better glycaemic control .
The BD Micro-Fine Ultra™ 4mm Pen Needle with Pentapoint technology has delivered a significant step forward in enhancing patient comfort and injection outcomes.
To see an animated demonstration of the BD Micro-Fine Ultra™ 4mm Pen Needle with Pentapoint technology visit: http://www.bdinteractivemedia.com/BDMicroFineUltra
For Media Enquiries Contact:
Laura Blott
PR Account Executive
Lindsell Marketing
00 44 207 402 0510
About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world’s most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of “Helping all people live healthy lives” by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.
Hirsch L, et al. The impact of a modified needle tip geometry on penetration force as well as acceptability, preference and perceived pain in subjects with diabetes. J Diab Sci Tech 2012.
Ibid. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-246.
Klobassa N, Moreland P. Psychological insulin resistance stems from fear. MayoClinic.com Living with Diabetes Blog, January 20, 2010. Available at: http://www.mayoclinic.com/health/psychological-insulin-resistance/MY01165. Accessed March 18, 2010.
Ibid. Hirsch L, et al. The impact of a modified needle tip geometry on penetration force as well as acceptability, preference and perceived pain in subjects with diabetes. J Diab Sci Tech 2012.
Hirsch L, Klaff L, Bailey T, Gibney M, Albanese J, Qu S, Kassler-Taub K. Comparative glycemic control, safety and patient ratings for a new 4 mm\32G insulin pen needle in adults with diabetes Curr Med ResOpin 2010;26:1531–1541
Frid A. Fat thickness and insulin administration, what do we know? Infusystems Int. 2006;5(3):17-19.
Gibney MA, Arce CH, Byron KJ, Hirsch LJ. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010 Jun;26(6):1519-30.
Polak M, Beregszaszi M, Belarbi N, et al. Subcutaneous or intramuscular injections of insulin in children: are we injecting where we think we are? Diabetes Care 1996;19(12):1434-1436.
Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabet Care 2008;31(9):e65.
Hofman PL, Lawton SA, Peart JM, et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med 2007;24:1400-1405.
Help employers find you! Check out all the jobs and post your resume.